Mubadala-backed M42 pitches genomics capabilities to the world

M42, an Abu Dhabi healthcare company backed by Mubadala, is pitching its genomic sequencing capabilities to governments and pharmaceutical companies worldwide. The firm has sequenced nearly 1 million genetic samples and is launching AI chatbots for chronic disease management, starting with kidney.com. M42 plans to expand its data-driven healthcare model globally and develop additional condition-specific platforms.